Share this post on:

290 (82.six) 50 (82.0) 247 (85.2) (eight.0) 43 (4.eight) 0.79(0.38.64) .00 8 (33.6) 233 (66.four) 07 (90.7) 90 (8.five) (9.three) 43 (eight.five) two.20 (.09.45) .0.Getting concerned HIV may perhaps pose a threat to members of the family Yes
290 (82.six) 50 (82.0) 247 (85.2) (8.0) 43 (four.eight) 0.79(0.38.64) .00 eight (33.6) 233 (66.four) 07 (90.7) 90 (8.5) (9.3) 43 (eight.five) 2.20 (.09.45) .0.Becoming concerned HIV may pose a threat to members of the family Yes No 268 (76.eight) 82 (23.two) 229 (85.four) 67 (eight.7) 39 (4.six) five (8.three) .32(0.68.53) .0.Sex with HIVpositive companion in preceding six months Yes No 295 (84.0) 56 (six.0) 253 (85.eight) 44 (78.6) 42 (four.2) 2 (two.four) .64(0.80.37) .0.Frequency of condom use in preceding six months Each and every time The majority of the time Sometimes Never ever 236 (80.0) two (7.) 3 (4.4) 25 (8.5) 20 (85.two) 20 (95.2) two (92.3) 20 (80.0) 35 (four.eight) (four.eight) (7.7) five (20.0) .00 three.48(0.456.79) two.09(0.266.58) 0.70 (0.25.98)0.0.23 0.49 0.50 0.Selfperceived likelihood of contracting HIV from HIVpositive partner Probably Unlikely 09 (3.) 242 (68.9) 0 (92.7) PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/20874419 96 (8.0) 8 (7.3) 46 (9.0) two.96 (.35.52) .Abbreviations: HIV, human immunodeficiency virus; AIDS, acquired immune deficiency syndrome; PrEP, preexposure prophylaxis; CI, self-assurance interval; OR, odds ratio. doi:0.37journal.pone.0067392.tPLOS One plosone.orgWillingness to use PrEP in HIVDiscordant CouplesTable 4. Connection among awareness ofuse ofattitudes toward PrEP and willingness to use PrEP.Willing to use oral PrEP Factors N Yes, n No, n, OR (95 CI)P value0.Ever heard of vaginal microbicides Yes No Ever heard of PEP Yes No Ever heard of PrEP Yes No 0 (two.eight) 34 (97.2) 8 (80.0) 289 (84.eight) two (20.0) 52 (five.2) 0.72(0.five.49) .00 34 (9.7) 37 (90.three) 28 (82.four) 269 (84.9) 6 (7.six) 48 (five.) 0.83 (0.33.two) .00 27 (7.7) 324 (92.three) 26 (96.3) 27 (83.six) (3.7) 53 (six.4) 5.09 (0.688.29) .0.0.Ever taken medicine to prevent sexually transmitted illness Yes No 7 (2.0) 344 (98.0) 6 (85.7) 29 (84.six) (4.3) 53 (5.4) .09 (0.three.26) .0.Worrying about becoming discriminated against by others as a result of oral PrEP use Yes No 92 (54.7) 59 (45.three) 45 (75.five) 52 (95.six) 47 (24.five) 7 (four.four) .00 7.04 (3.086.67)0.Abbreviations: PEP, postexposure prophylaxis; PrEP, preexposure prophylaxis; CI, confidence interval; OR, odds ratio. doi:0.37journal.pone.0067392.tWillingness to use oral PrEP and issues related to its useA total of 297 participants (84.6 ) had been willing to utilize oral PrEP if verified each productive and protected. The remaining 54 participants (5.four ) had been unwilling to utilize oral PrEP for the reason that three (57.4 ) believed they have been at no risk of contracting HIV, or 28 (5.9 ) have been concerned about its security, or two (22.2 ) doubted its efficacy. Among participants willing to make use of oral PrEP, 258 (86.8 ) were concerned about its efficacy, 249 (83.eight ) were concerned about its security, 90 (64.0 ) have been concerned about its expense, and 45 were concerned about its availability (5.2 ). Regarding social issues, three (38.0 ) participants had no worry of disclosing their use of PrEP to other people.Multivariate MedChemExpress Acetovanillone logistic regression analysis of elements connected with willingness to use oral PrEPIn multivariate logistic regression analysis, willingness to make use of oral PrEP was coded as “”, and unwillingness to utilize oral PrEP was coded as “0”. Variables that were substantial (P,0.2) inside the univariate analysis have been entered in to the initial multivariate logistic model; these variables included “age”, “ethnicity”, “monthly household income”, “having a very good awareness of HIVAIDS”, “sex with HIVpositive partner in the previous six months”, “awareness of vaginal microbicides”, “it is difficult to stop HIVAIDS when cohabiting with a HIVpositive partner”, “selfperceived likelihood of contracting HIV from an HIVpositiveAcceptability of oral PrEP in.

Share this post on:

Author: bet-bromodomain.